PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-12.41%
Negative revenue growth is a classic Benjamin Graham warning sign. While possibly cyclical, verify Market Share trends and Competitive Position.
No Data
No Data available this quarter, please select a different quarter.
-12.41%
Negative gross profit growth is a serious warning sign. Benjamin Graham would demand thorough analysis of pricing power and cost structure.
No Data
No Data available this quarter, please select a different quarter.
29.66%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
16.61%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.48%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
25.48%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
3.10%
D&A growth 0-5% reflects moderate asset expansion. Benjamin Graham would check if growth drives future value.
-28.10%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
-46.25%
Negative EBITDA margin growth needs thorough analysis. Benjamin Graham would examine operational issues.
-27.47%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
-45.52%
Negative operating margin growth needs thorough analysis. Benjamin Graham would examine operational issues.
-14.81%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-27.92%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
-46.04%
Negative pre-tax margin growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-27.92%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
-46.04%
Negative net margin growth needs thorough analysis. Benjamin Graham would examine operational issues.
-20.00%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-20.00%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
6.47%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
6.47%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.